Company Encyclopedia
View More
name
CF PHARMTECH
02652.HK
CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs in the field of respiratory diseases in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment of respiratory diseases, including allergic rhinitis, asthma, chronic obstructive pulmonary, respiratory infection, pulmonary fibrosis, pulmonary hypertension, and other respiratory diseases.
1.466 T
02652.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Top 10 HK Stock Losers (12.8)

    REFIRE(02570) fell 27.33%, with a trading turnover 403.5 Million HKD, and a year-to-date fell 47.6%. INNOGEN-B(02591) fell 14.32%, with a trading turnover 55.0 Million HKD, and a year-to-date rose 101.8%. CHINA QINFA(00866) fell 11.25%, with a trading turnover 115.0 Million HKD, and a year-to-date rose 153.6%.

    Top Gainers & Losers·
    HK
    02570
    -13.07%
    HK
    02591
    -14.69%
    HK
    00866
    -7.75%
    Top Gainers & Losers·
    HK
    02570
    -13.07%
    HK
    02591
    -14.69%
    HK
    00866
    -7.75%

    CF PharmTech Inc. Announces Date for First Extraordinary General Meeting in 2025

    CF PharmTech, Inc. will hold its first extraordinary general meeting of 2025 on December 16, 2025, in Suzhou, Jiangsu, PRC. Shareholders will consider the proposed authorization for the Board to handle matters related to the H Share Award Scheme.

    Reuters·
    HK
    02652
    +1.08%
    Reuters·
    HK
    02652
    +1.08%

    CF PharmTech Inc. to Seek Shareholder Approval for H Share Award Scheme and Board Authorization at Upcoming Meeting

    CF PharmTech Inc. is seeking shareholder approval for the 2025 H Share Award Scheme at its upcoming general meeting. The scheme aims to attract and retain key talent by aligning employee and shareholder interests. Shareholders are encouraged to vote in favor of the proposal, with further details to be provided in a forthcoming circular. The meeting date will be announced soon.

    Reuters·
    HK
    02652
    +1.08%
    Reuters·
    HK
    02652
    +1.08%

    Understanding the Market | CF PHARMTECH rose nearly 3% before noon as the company's minimally invasive intervention device for treating emphysema completed its first enrollment

    CF PHARMTECH's stock price rose nearly 3% before noon, reaching HKD 29.2, with a transaction volume of HKD 5.3645 million. The company announced that its self-developed bronchial valve lung volume reduction device successfully completed the enrollment of its first subject, marking the beginning of the clinical validation phase, aimed at providing minimally invasive treatment options for patients with emphysema and other chronic obstructive pulmonary diseases. The study will evaluate the safety and technical success rate of the device and observe changes in key clinical outcomes

    Zhitong·
    HK
    02652
    +1.08%
    Zhitong·
    HK
    02652
    +1.08%

    Brief News: CF PHARMTECH surged 181% with an oversubscription of 6,700 times

    CF PHARMTECH Co., Ltd. was listed in Hong Kong on Wednesday, opening with a 219% increase, and closing at HKD 41.5 at noon, up 181%. The company issued nearly 41.2 million H shares, with the public offering oversubscribed by nearly 6,697 times and the international placement oversubscribed by 11.7 times, raising a net amount of HKD 525 million. CF PHARMTECH focuses on inhalation technology and drug research and development, with first-quarter revenue falling 2.7% to 136 million yuan, while profit more than doubled to 12.815 million yuan

    BambooWorks·
    HK
    02652
    +1.08%
    BambooWorks·
    HK
    02652
    +1.08%
    © 2025 Longbridge｜Disclaimer